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Abstract  
Rationale: With increasing survival of preterm infants with bronchopulmonary dysplasia 
(BPD) it is critical to understand the clinical consequences on adult lung health. 
Objectives: To assess structural and functional lung parameters in young adult BPD survivors 
and preterm and term controls 
Methods: Young adult survivors of BPD (mean age 24) underwent spirometry, lung volumes, 
transfer factor, lung clearance index and fractional exhaled nitric oxide measurements 
together with high-resolution chest tomographic CT imaging and cardiopulmonary exercise 
testing. 
Measurements and main results: 25 adult BPD survivors, (mean ± SD gestational age (GA) 
26.8 ± 2.3 weeks; birth weight 866 ± 255 g), 24 adult prematurely born non-BPD controls (GA 
30.6 ± 1.9 weeks; birth weight 1234 ± 207 g) and 25 adult term birth controls (GA 38.5 ± 0.9 
weeks; and birth weight 3569 ± 2979 g) were studied. BPD subjects were more likely to be 
wakened by cough (OR 9.7, 95% CI: 1.8 to 52.6), p<0.01), wheeze and breathlessness (OR 
12.2, 95%CI: 1.3 to 112), p<0.05) than term controls after adjusting for gender and current 
smoking. Preterm subjects had greater airways obstruction than term subjects. BPD subjects 
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had significantly lower values for FEV1 and FEF25-75 (% predicted and z scores) than term 
controls (both p<0.001). Although non-BPD subjects also had lower spirometric values than 
term controls, none of the differences reached statistical significance. More BPD subjects 
(25%) had fixed airflow obstruction than non-BPD (12.5%) and term (0%) subjects (p=0.004).  
Both BPD and non-BPD subjects had significantly greater impairment in gas transfer (KCO % 
predicted) than term subjects (both p<0.05). Eighteen (37%) preterm participants were 
classified as small for gestational age  (birth weight < 10th percentile for gestational age). 
These subjects had significantly greater impairment in FEV1 (% predicted and z scores) than 
those born appropriate for gestational age. BPD survivors had significantly more severe 
radiographic structural lung impairment than non-BPD subjects. Both preterm groups had 
impaired exercise capacity compared to term controls. There was a trend for greater 
limitation and leg discomfort in BPD survivors.   
Conclusions: Adult preterm birth survivors, especially those who developed BPD, continue to 
experience respiratory symptoms and exhibit clinically important levels of pulmonary 
impairment. 
 
Abstract word count: 350 
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Children born prematurely and especially those who develope bronchopulmonary dysplasia 
(BPD) have more respiratory symptoms (1, 2) and greater lung function impairment 
persisting through adolescence than term born peers (2, 3, 4) Consequently concerns 
regarding the longer-term consequences of BPD include the early development of chronic 
obstructive pulmonary disease (COPD) (5, 6). The adult respiratory health outcomes of BPD 
survivors are not well defined and our recent systematic review highlighted the limited 
number of small studies, some without suitable study controls (7).  
 
Although we have recently undertaken a study of adult survivors of BPD in their third and 
fourth decade of life and reported increased respiratory symptoms and substantial and 
clinically important reductions in lung function variables reflecting airflow obstruction 
compared to preterm and term controls, important knowledge gaps remain.  Specifically, it 
is unclear whether lung impairment extends beyond the airway and if lung injury in early 
preterm life is associated with structural damage to surrounding lung tissue.  
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One small study of highly selected and symptomatic adult BPD subjects reported striking 
structural damage including emphysema (8). Furthermore lung impairment may only 
become apparent during exercise and to date results from cardiopulmonary exercise testing 
have been conflicting. Vrijlandt and colleagues (9) confirmed reduced peak oxygen 
consumption in young adult BPD subjects compared to healthy controls. Lovering and 
colleagues (10) confirmed significantly reduced peak work rates and greater leg discomfort 
during exercise in preterm non-BPD and BPD subjects compared to term controls. In 
contrast, Narang et al (11), found no evidence of exercise limitation in ex preterm subjects 
compared to term controls.  
 
Based on the accumulating evidence we hypothesised greater structural and functional lung 
impairment in adult BPD survivors compared to preterm and term controls.  Here we report 
on lung function (spirometry, lung volumes, diffusing capacity), lung clearance index, 
fractional exhaled nitric oxide (FeNO) measurements, exercise capacity and high resolution 
CT (HRCT) findings in an index group of adult survivors of BPD compared to preterm and 
term controls. We used a subset of our Premature Adult Lung Study (PALS) cohort which was 
previously published (12) and reported in abstract form (13, 14, 15, 16, 17). 
 
Methods 
Study design and participants  
The PALS cohort comprised adults previously cared for in the Regional Neonatal Intensive 
Care Unit (NICU) of the Royal Maternity Hospital, Belfast between January 1978 and April 
1993. This unit was the regional centre providing a comprehensive neonatal service and 
received patients from all over Northern Ireland.  
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BPD was defined as the continued requirement for supplemental oxygen >28 postnatal days 
with chronic radiological changes and severity (mild, moderate or severe) was graded 
according to oxygen requirements at 36 weeks post menstrual age (18). BPD subjects were 
compared with gender matched preterm non-BPD controls also cared for in the NICU but 
not requiring mechanical ventilation or prolonged respiratory support.  Both preterm groups 
were of very low birth weights (VLBW: < 1500g). A second control group comprising full term 
individuals, with no history of respiratory disease was recruited.  
 
Tracing and recruitment to PALS and this sub study (Figure E1) is detailed in the online 
supplement. Consecutive subjects responding to an invitation to participate in this sub study 
and meeting study criteria were recruited. Subjects were excluded if physical or cognitive 
impairment was likely to prevent them undertaking study procedures. (See online 
supplement for full protocol). All participants gave written informed consent and the study 
was approved by the Office for Research Ethics Committees Northern Ireland (ORECNI, 
11/NI/0042).  
 
Testing Protocol: Visit one 
Respiratory symptoms were recorded using the European Community Respiratory Health 
Survey (ECRHS) screening tool (19). Quality of life was measured using the EuroQol (20) and 
lung function tests were carried out in the order described below. 
 
Multiple breath washout tests were performed using a modified InnocorTM gas analyser 
(InnovisionTM A/S, Odense, Denmark) and an open-circuit technique (21) with the lung 
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clearance index calculated. FeNO was measured using the (NIOXTM MINO (Aerocrine AB, 
Sweden) according to ATS/ERS recommendations (22).  
 
Forced Vital Capacity (FVC), and Forced Expiratory Volume in one second (FEV1) and mid 
expiratory flow (FEF25-75) were measured in accordance with ATS/ERS guidance (23) using a 
Sensoromics Vmax Encore (Conshohocken, USA). Spirometric results were expressed as 
percent predicted and z-scores based on prediction equations provided by the Institute of 
Child Health (24).  
 
Total Lung Capacity (TLC) and Residual Volume (RV) were measured using Helium dilution. 
Diffusing capacities were measured using single breath diffusing capacity tests. Subjects 
omitted regular asthma medication the morning of testing. 
 
BPD subjects and non-BPD controls underwent inspiratory and expiratory HRCT imaging of 
the chest on a 64-slice CT scanner (Siemens AG, Germany).  All scans were scored 
independently and blindly by two expert radiologists (SG, JC) using a validated standardised 
scoring method (Table E1 online supplement) (25).  
 
Testing Protocol: Visit Two 
Exercise testing was performed using a standardised, symptom-limited, maximal exercise 
protocol, (Modified Bruce Protocol) (26) using ATS guidelines (27). Peak VO2 was defined as 
the average VO2 over the final 30 seconds of exercise.  The anaerobic threshold was 
determined using the V slope method by two experienced observers (SC, JM). Exercise data 
were plotted as time weighted 10 second averages. 
9 
 
 
Statistical analysis 
Continuous variables were summarised as mean (standard deviation, SD) if normally 
distributed and median (interquartile range, IQR) if skewed. For normally distributed 
variables group comparisons were made using one-way ANOVA (with Tukey’s post-hoc all 
pairs simultaneous 95% confidence intervals for mean differences and p-values) or t-tests.  
 
For non-normally distributed variables group comparisons were made using Kruskal-Wallis 
test (with Dunn’s all pairs post-hoc testing) or Mann-Whitney U tests. Categorical variables 
were summarised as proportions and comparisons performed using the chi-square test (or 
Fisher’s exact test, where appropriate) and summarised as odds ratios.  
 
We used linear regression modelling to compare lung function for those with BPD and 
Preterm Non BPD whilst adjusting for birth weight, gestational age and year of birth.   
Logistic regression was used to compare symptoms between groups whilst adjusting for 
gender and current smoking status.  
 
We undertook analysis to determine the effect of low birth weight for GA by comparing 
those born small for gestational age (SGA) with those born at an appropriate weight for 
gestation (AGA). SGA was defined as a birth weight < 10th percentile for gestational age 
using the 1990 British Growth Standard (28).  These comparisons of SGA and AGA subgroups 
required weighting to take account of the different selection probabilities for the BPD and 
non-BPD subgroups inherent in our study design.  
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SPSS version 20 (IBM Corp., Armonk, New York), Minitab 17 (Minitab Inc., State College, 
Pennsylvania) and Stata release 12 (Stata Corp, College Stations, Texas) were used in the 
statistical analysis. A p-value ≤ 0.05 was taken as statistically significant 
 
Results 
Twenty five BPD subjects (mean (SD) age 24.0 (3.4)y, range 19 to 33y) were enrolled and 
compared with 24 non-BPD controls (mean (SD) age 26.4 (3.7)y, range 21 to 34y) and 25 
term controls (mean (SD) age 28.3(3.3)y, range 22 to 33y). Of these, 23 BPD subjects (15% of 
the original 153 identified from labour records) and 23 non BPD (7% of original 322 non-BPD 
subjects from labour records) completed all parts of this study.  
 
Term controls comprised 12 (2% of original 492 identified from labour records) and 13 
healthy volunteers born term with known birth weight and GA recruited from hospital staff. 
Participant demographics are detailed in Table 1.  
 
BPD subjects had a lower gestational age [mean 26.8 weeks (SD 2.3, range 23 to 30 weeks)] 
compared to non-BPD subjects [mean 30.6 (SD 1.9, range 26 to 34) weeks] and lower birth 
weight [mean 866 (SD 255, range 510 to 1490) grams] compared to non-BPD subjects [mean 
1234 (SD 205, range 760 to 1500) grams, (both p<0.001)].  
 
Current smoking status, BMI and physician diagnosed asthma were not significantly different 
among groups. One BPD subject was receiving inhaled corticosteroids and a short acting 
beta 2 agonist and 2 others were prescribed short acting beta 2 agonists alone. No non-BPD 
subjects were prescribed inhaled corticosteroids although one was prescribed a short acting 
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beta 2 agonist. One term control had been prescribed an inhaled corticosteroid/long acting 
beta 2 agonist while 3 others took short acting beta 2 agonists alone.  
There were no significant differences in gestation between BPD subjects recruited and those 
not responding to invitation but the responders were on average 150 lighter in birth weight 
(Table E2, online supplement).  
 
Respiratory symptoms 
BPD subjects were at almost 10 times more likely to report being woken by coughing (OR 
9.7, 95% CI: 1.8 to 52.6), p<0.01), and were over 4 times more likely to report being 
breathless when wheezing (OR 4.3, 95%CI: 1.1 to 16.8), p<0.05) in the last 12 months 
compared to term controls after adjusting for gender and current smoking (Table E3 online 
supplement). BPD subjects had significantly lower EQ-5D utility score than term controls 
(p<0.01) and reported lower scores on EQ-5D VAS compared with non-BPD, although this 
was not statistically significant (Table E4, online supplement).  
 
Lung function 
Significant differences were apparent between the 3 groups in all lung function tests with 
the exception of RV % predicted, TLC % predicted and RV/TLC ratio (Table 2 and Figure 1).  
BPD subjects had significantly lower values for all spirometric measures than term controls. 
Although non-BPD subjects also had lower spirometric values than term controls, none of 
the differences reached statistical significance.  
 
BPD subjects had significantly lower mean values for FEV1, FVC and FEF25-75 compared to 
non-BPD controls whether expressed as percent predicted or z-scores (Table 2). Of the 7 BPD 
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subjects who had an FEV1/ FVC ratio < 70 % predicted only 2 had significant reversibility 
defined as change in FEV1 of > 400mls and FEV1 % predicted > 15 % after bronchodilator (23).  
 
While not statistically significant, RV/TLC ratios were higher in the BPD subjects than preterm 
and term controls. Diffusing capacities TLCO and KCO % predicted values were similar in BPD 
and non-BPD subjects and both were significantly lower than term controls (both p<0.001).   
 
Significantly more BPD subjects had airflow reductions in the abnormally low range defined 
as FEV1 < 80% predicted, FEV1/FVC <70%, FEF25-75 < 60% predicted, TLCO % predicted < 80%, 
KCO % predicted <80%). Almost one quarter of the BPD group had FEV1 <80% compared to 
none of the term controls. Similarly, 60% of BPD subjects had FEF25-75 <60% compared to less 
than 5% of term controls.  
 
Abnormally increased RV/TLC ratios (i.e. >120 % predicted) were recorded in 38% of BPD 
subjects compared with less than 5% of term controls. 43% of BPD subjects had abnormally 
low TLCO % predicted and 23 % abnormally low KCO % predicted compared to term controls 
(4% and 0% respectively) (both p<0. 01) . Compared to non-BPD controls, significantly more 
BPD subjects had abnormally low FEF25-75 % predicted values (p<0.01) (Table E5 online 
supplement).  
 
As our study population comprised adults born preterm over a 15 year time span we 
considered the possibility that our comparisons of groups could be confounded by birth 
cohort effects as well as by birth weight and gestational age differences.  Regression analysis 
of the lung function measurements (Table E6 online supplement).   
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Lung Clearance Index  
Lung clearance index scores were significantly higher in BPD subjects [median (IQR) 7.0 (6.7-
7.9)] compared to non-BPD [6.1 (5.9-6.9)] and term controls [6.6 (5.9-7.0)] (p=0.016 and 
p=0.003). Using our recently published normal values [mean (SD) 6.5 (0.5)] for lung clearance 
index by multiple breath washout on the same device in a cohort (n=30) of healthy controls 
(Section E1.2) (29) more BPD subjects (n=6) had abnormal lung clearance index values (> 
1.96 SD score i.e. > 7.5) compared with non-BPD (n=2) and term (n=1) controls (p=0.055). 
Thirty percent of BPD subjects with normal FEV1 (>80% predicted) had abnormal lung 
clearance index measurements (22). 
 
FeNO measurements  
Although FeNO measurements were lower in both BPD subjects (median 19, IQR: 12 to 28 
ppb) and non-BPD controls (median 19, IQR: 12 to 28 ppb) compared to term controls 
(median 27, IQR: 14 to 43 ppb) neither result attained statistical significance.   
 
Lung function of subjects with low versus appropriate birth weight for gestational age  
Eighteen (37%) preterm participants were classified as SGA (birth weight < 10th percentile for 
gestational age). Data are presented in table 3. The SGA participants had been born at 
significantly greater gestational age than AGA (mean difference (95%CIs), -2.4 weeks (1.5 to 
4.1), p < 0.001). SGA subjects had significantly greater impairment in FEV1 (% predicted than 
those born AGA (mean difference (95%CI), -9.8 (-19.3 to -0.2), p<0.05) but this difference did 
not retain its significance after weighting the analysis to allow for the higher sampling 
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fraction of BPD subjects than non-BPD subjects. Those with BPD were no more likely to be 
SGA as preterm non-BPD (32% versus 42%, chi-squared p=0.69).  
 
HRCT chest Imaging  
BPD subjects had higher HRCT scan severity scores than non-BPD (p=0.0001) and all BPD 
subjects had some degree of HRCT abnormality (Figure E2 and E3, Table 4). Sub-pleural 
opacities were the most common abnormality detected, and more common in BPD than 
non-BPD subjects (96% v 43%, p<0.001). Hypoattenuation on expiration (gas trapping) and 
bullous disease were significantly more common in BPD than non-BPD (65% v 30%, and 22% 
v 0%, both p<0.05). There were no significant differences in emphysema, bronchiectasis or 
bronchial wall thickening between groups.    
 
When all preterm subjects were considered together, increasing HRCT score severity 
correlated significantly with measures of airflow obstruction (lower FEV1 z-scores, FEV1/FVC 
z-scores, FEF25-75 z-scores) and hyperinflation (increased RV/TLC ratio).  When only BPD 
subjects were considered, only the correlation between HRCT score and RV/TLC ratio 
remained significant. 
 
Cardiopulmonary exercise testing  
Exercise data were obtained from 22 BPD subjects, 20 non-BPD and 24 term controls (Table 
5). Two BPD subjects were unable to perform the test because of cerebral palsy. One BPD 
subject, 2 non-BPD and 1 term control failed to attend. A greater proportion of term controls 
exercised more than 3 hours/week with no other significant differences in weekly activity 
levels among study groups. Fatigue and dyspnoea were the most common reason for 
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terminating the test in each group.  More subjects with BPD (n=7) reported leg discomfort 
during exercise than non-BPD (n=4) and term controls (n=3).  
 
 
BPD subjects had significantly lower peak VO2 than term controls [Mean (SD) ml/kg/min: 
35.6 (7.5) vs. 45.2 (11.3) (p<0.01) and travelled significantly less distance than term controls 
[Mean (SD) m: 966 (245) vs. 1402 (333) (p<0.001)]. Non-BPD controls had significantly lower 
peak VO2 than term controls [39.3 (8.8) vs. 45.2 (11.3) (p<0.05)] and also travelled 
significantly less distance than term controls [1143 (303) vs. 1402 (333), p<0.05)]. A number 
of BPD subjects (n=6) failed to attain >84% of their predicted target heart rate. Even when 
these subjects were excluded the significant differences in peak VO2 between BPD subjects 
and term controls remained [Mean (SD) ml/kg/min: 36.9 (7.2) vs. 46.1 (10.8) (p<0. 01). BPD 
subjects achieved lower peak VO2 and travelled shorter distances than non-BPD but these 
differences were not statistically significant. 
 
At peak exercise, BPD subjects had significantly lower peak heart rates than term controls 
(mean (SD) bpm: 173(13) vs. 186 (14), p<0.001). Ventilatory equivalents for CO2 and O2 at 
the AT were greater in the BPD group than in the term controls, but there were no 
significant differences in ventilatory reserve or maximum respiratory rates between BPD 
subjects and term controls. BPD subjects had significantly lower minute ventilation (VE 
l/min) [Mean (SD) (l/min): 78.3 (22.7) vs. 109.5 (36.2); (p<0.01)] and smaller tidal volume (Vt, 
L) [1.75 (0.45) vs. 2.75 (0.67); (p<0.001)] at peak exercise than term controls.  
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Measures of airflow obstruction [FEV1 % predicted (r=0.29, p=0.001), FEV1/FVC ratio (r=0.01, 
p=0.05) and FEF25-75 % predicted (r=0.32, p=0.04] were significantly correlated with impaired 
exercise capacity in adult survivors of BPD. However, HRCT scan severity scores were not 
associated with exercise capacity in preterm adults. There were no neonatal factors that 
could significantly predict impaired exercise capacity in preterm subjects. 
 
Discussion 
In this study, we confirm that individuals born prematurely, in particular those who 
developed BPD, have clinically important levels of respiratory morbidity persisting into 
adulthood. Young adult BPD survivors reported more wheeze, breathlessness and wakening 
with cough than non-BPD or term controls and significantly more had fixed airflow 
obstruction in the presence of normal or low FeNO levels and decreased diffusion capacity. 
BPD survivors had radiological evidence of more severe structural lung impairment than 
non-BPD controls. We also observed that both preterm groups had impaired exercise 
capacity compared to term controls with a trend for greater exercise limitation and more leg 
discomfort during exercise in BPD survivors.   
 
Our findings reaffirm the evidence suggesting adverse long term consequences of preterm 
birth and BPD on adult respiratory health (4, 11, 29-31). We extend our previous 
observations and suggest lung function abnormalities are not confined solely to spirometric 
end points, but include air trapping and impaired gas transfer (12). In the majority (75%) of 
BPD survivors, airflow obstruction was fixed or only partially reversible and was associated 
with normal or low FeNO values suggesting a non-asthmatic or at least a non-eosinophilic 
cause for airflow limitation.  
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This observation adds support to the concern that perinatal lung injury may predispose to 
early COPD (6).  
In a recent study by Landry and colleagues (32), adults born prematurely with BPD were 
more likely to have mild airflow obstruction and bronchial hyperresponsiveness than those 
born prematurely who did not experience BPD. We did not undertake methacholine 
challenge testing butthe presence of fixed airflow obstruction in a number of our subjects 
suggests that distinct phenotypic variants of airflow limitation exist in adult survivors of 
preterm birth.  
 
Significantly lower FVC (% predicted and z scores) were observed in BPD subjects compared 
to term born although restrictive defects were not seen as no subjects had FVC and/or TLC  
measurements below the lower limit of normal.   Although mean birth weights were lower in 
BPD subjects compared to non-BPD adjustment for birth weight did not alter our findings. As 
none of the non-BPD preterms were ventilated we suspect the inflammatory effects on lung 
development in early neonatal life due to hyperoxia and barotrauma and possible infection 
during the periods of mechanical ventilation have contributed to differences between the 
preterm groups.   Lung clearance index measured by multiple breath washout is a measure 
of ventilation distribution which may become heterogeneous (uneven) early in diseases 
including asthma (33) and cystic fibrosis (34). We observed a greater proportion of adult BPD 
survivors with abnormal values compared to term. Although measurements were not as high 
as reported in bronchiectasis (29) a significant proportion (30%) of BPD subjects with normal 
spirometry, had abnormal lung clearance index measurements.  
We investigated the association between neonatal factors and lung function in our preterm 
population. We adjusted for year of birth and found no evidence of a birth cohort effect. We 
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sought to determine whether low birth weight for gestational age could explain some of our 
findings and report that those born SGA had greater lung function impairment than subjects 
born AGA. Infants with intra-uterine growth retardation are at increased risk of impaired 
lung function within the first few years of life (35). Here we provide evidence that 
impairment extends into adulthood.  
Structural lung abnormalities on CT scans have been reported in children and adolescents 
surviving BPD (25, 36).  We found that BPD subjects have significantly more radiological 
abnormality compared to non-BPD controls. Subpleural opacities were the most common 
abnormality observed in almost all (96%) of our BPD subjects compared with less than half 
(46%) of non-BPD subjects. They are thought to be related to fibrotic change within the lung 
arising from neonatal insults such as hyperoxia and mechanical ventilation. We did not see 
significant bullous lung disease contrasting the findings of Wong et al, (8). We observed 
significant inverse relationships between spirometry measurements and HRCT score severity 
and highlight important ‘structure-function’ consequences of preterm birth on adult lung 
health.  We observed significantly impaired exercise capacity in preterm subjects (BPD and 
non BPD) compared to term controls. Following adjustments for sub-maximal exercise tests 
(Table E9) and general activity levels, these significant differences remained. BPD subjects 
had numerically greater reductions in peak VO2 and distance travelled on the treadmill than 
the preterm non-BPD controls which could possibility be due to patient effort as they 
achieved lower peak heart rates lower RERs. At least some of the reduction in exercise 
capacity in both our preterm groups may have been due to deconditioning as the VO2 at 
AT/peak VO2 was lower in these groups than in term controls.  The slightly low 
oxyhemoglobin saturation and elevated ventilatory equivalents in BPD subjects suggest mild 
impairment of gas exchange during exercise, but these abnormalities did not limit exercise 
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as indicated by the normal ventilatory reserve.  Our finding of impaired exercise capacity in 
adults born preterm is in line Vrijlandt et al (9) but contrasts Narang and colleagues (11), 
who observed no differences between preterm and term subjects. Their preterm group had 
relatively well preserved lung function and included few (n=7) BPD subjects. A recent study 
by Lovering and colleagues (10) identified reduced exercise capacity in adult preterm 
survivors which was independent of BPD or exercise induced expiratory flow limitation. We 
did not undertake measurements of expiratory flow or dynamic hyperinflation during 
exercise. However reduced lung function and low lung diffusion capacity alone do not 
appear to explain the reduced exercise capacity observed in adult survivors of preterm birth 
(37).  Other unidentified aspects of BPD which might influence exercise performance include 
deconditioning or perception of fatigue. Landry and colleagues reported that BPD subjects 
tended to be more sedentary than non-BPD and term subjects (32). In line with Lovering and 
colleagues (10) a greater proportion of our preterm subjects reported leg discomfort during 
exercise which may simply reflect deconditioning but does raise the possibility of impaired 
peripheral muscle function as an additional longer term consequence of preterm birth.  
Strengths and Limitations 
 
A key strength was the ability to trace and study in adulthood, a group of carefully 
characterised preterm infants (BPD subjects and non-BPD controls) all cared for in the same 
hospital. Further, our study size was larger than many identified in our systematic literature 
review (7).  
A potential limitation of our study was the relatively low recruitment rates of preterm adults 
from the infants identified in the original labour records. This may have introduced bias such 
as exclusion of the most severely affected although the similarity of birth demographics 
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between the PALS cohort and those not responding to the study invitation suggests our 
findings are broadly representative of the general preterm population.  
 
Although less applicable to infants with ‘new’ BPD arising from extreme prematurity, our 
findings are relevant to the large number of BPD survivors currently in their third and fourth 
decade of life many of whom may have unrecognised or incorrectly diagnosed respiratory 
disease. There is a need for increased awareness as recent evidence suggests that few 
physicians enquire about neonatal events when assessing their adult patients with 
pulmonary complaints (38).  
 
None of the non-BPD subjects were ventilated during the neonatal period which does raise a 
potential bias when directly comparing BPD and non-BPD subjects. Further, non-BPD 
preterms had higher mean GA and birth weight than BPD preterms and although we 
undertook linear regression to simultaneously correct for these variables were we not able 
to adjust for all potential factors.  
 
Finally, as this is a cross-sectional study we have no information on earlier or later lung 
function trajectories for this cohort. Following preterm cohorts from early life through 
adulthood into later life is crucial to a complete understanding the consequences of lung 
injury in the neonatal period.   
 
Conclusions 
Adult survivors of preterm birth have evidence of airflow obstruction which is fixed or only 
partially reversible. In addition we observed impaired levels of exercise capacity in those 
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born preterm compared to full term which could not be explained solely by structural 
changes or lung function impairment. Whether this impairment is progressive requires 
longitudinal follow up of preterm cohorts.   
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Figure legend 
Figure 1: Graphical summary of % predicted (mean ± SD) for airflow and gas transfer 
variables between study groups. BPD subjects had significantly lower values for all 
displayed measures than term controls groups (FEV1, FVC and FEF25-75, all p<0.001; 
KCO p< 0.001).  Non-BPD subjects also had lower spirometric values than term 
controls but none of the differences reached statistical significance. BPD subjects had 
significantly lower mean values for FEV1 and FEF25-75 (% predicted) (both p<0.01) 
compared to non-BPD controls.  
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Table 1: Demographics of study participants 
 BPD Non BPD Term BPD vs. non BPD BPD vs. Term Non BPD vs. Term 
Number, n 25 24 25    
Birth weight, g 866 (255) 1234 (205) 3569 (297) -369 (-544 to -194) *** -2704 (-2877 to -2530) *** -2335 (-2510 to -2160) *** 
Gestational age, wk 26.8 (2.3) 30.6 (1.9) 38.5 (0.9) -3.8 (-5.0 to -2.6) *** -11.6 (-12.9 to -10.4) *** -7.9 (-9.1 to -6.6) *** 
Duration of IPPV, h 966 (599-1652) n/a n/a    
Duration O2 >60 %, h 10  (2-99) n/a n/a    
Maternal Smoker 7/19 (37%) 8/18 (44%) n/a 0.7 (0.2 to 2.7)   
Antenatal Steroids 5/25 (20%) 8/24 (33%) 0/25 (0%) 0.5 (0.1 to 1.8)   
Postnatal Steroids 10/25 (40%) 0/24 (0%) 0/25 (0%)    
Surfactant 8/25 (32%) 0/24 (0%) 0/25 (0%)    
Apgar Score 1 min 5 (3-6) 7 (3-8) n/a -1 (-3 to 0)   
Apgar Score 5 min 8 (7-9) 9 (8-9) n/a -1  (-2 to 0)**   
BPD Moderate or Severe 13/25 (52%) n/a n/a    
Gender, male 14/25 (56%) 14/24 (58%) 15/25 (60%) 0.9 (0.3 to 2.8) 0.8 (0.3 to 2.6) 0.9 (0.3 to 2.9) 
Age at study, y 24.0 (3.4) 26.4 (3.7) 28.3 (3.3) -2.4 (-4.8 to 0.0)* -4.3 (-6.6 to -1.9)*** -1.8 (-4.2 to 0.5) 
Height, cm 163.7 (10.8) 166.4 (11.6) 173.7 (7.5) -2.7 (-9.6 to 4.2) -10.0 (-16.9 to -3.2)** -7.4 (-14.3 to -0.5)* 
Body mass index, kg/m2 25.0 (5.6) 22.7 (3.4) 24.9 (3.6) 2.3 (-0.9 to 5.4) 0.1 (-3.0 to 3.1) -2.2 (-5.3, 0.9) 
Physician-diagnosed Asthma 4/25 (16%) 1/24 (4%) 4/25 (16%) 4.4 (0.4 to 42) 1.0 (0.2 to 4.5) 0.2 (0.0 to 2.2) 
Current smoker† 2/25 (8%) 5/24 (21%) 2/25 (8%) 0.3 (0.1 to 1.9) 1.0 (0.1 to 7.7) 3.0 (0.5 to 17) 
Exercise at least 2-3 hr/week 6/24 (25%) 5/22 (23%) 14/22 (64%) 1.1 (0.3 to 4.4) 0.2 (0.1 to 0.7)* 0.2 (0.1 to 0.7)* 
Data are presented as mean (SD), median (IQR) or n(%) 
Between group comparisons are presented as difference in means (95%CI), differences in medians (95%CI) or odds ratios (95%CI)  
n/a – not available 
* : p<0.05, **: p<0.01,***: p<0.001 
† Daily smoker at the time of testing. 
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Table 2 Static lung function and gas transfer tests compared between preterm BPD and control groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BPD  
(n=25) 
Non BPD 
(n=23)  
Term 
(n=25) 
BPD vs. non BPD  BPD vs.Term  Non BPD vs. Term 
       
FEV1 % pred. 88.2 (15.2) 102.0 (14.9) 109.4 (11.8) -13.8 (-23.5 to 4.1)** -21.2 (-30.7 to -11.7)***  -7.3 (-10.0 to 2.4) 
FEV1 z-score -1.19 (1.27) 0.01 (1.27) 0.49 (0.91) -1.20 (-2.00 to -0.40)** -1.68 (-2.46 to -0.89)*** -0.48 (-1.27 to 0.32) 
FVC % pred. 101.8 (15.0) 110.2 (13.8) 115.7 (9.4) -8.5 (-17.5 to 0.5) -14.0 (-22.7 to -5.2)*** -5.5 (-14.4 to 3.5) 
FVC z-score -0.11 (1.22)  0.46 (1.24) 0.77 (0.83) -0.57 (-1.34 to 0.20) -0.88 (-1.63 to -0.13)* -0.31 (-1.07 to 0.46) 
FEV1/FVC ratio % pred. 75.0 (9.1) 80.2 (9.9)  81.1 (7.1) -5.2 (-11.3 to 0.8) -6.1 (-12.0 to -0.2)* -0.9 (-6.9 to 5.2) 
FEV1/FVC z-score -1.21 (0.99)  -0.45 (1.10) -0.17 (1.08) -0.76 (-1.49 to -0.03)* -1.05 (-1.76 to -0.33)** -0.28 (-1.01 to 0.45) 
FEF25-75 % pred. 59.0 (21.5) 80.7 (26.0)  90.8 (20.3) -21.7 (-37.4 to -6.1)** -31.8 (-47.1 to -16.5)*** -10.1 (-25.7 to 5.6) 
FEF25-75% z-score -1.55 (1.34) -0.41 (1.26) -0.07 (0.96) -1.14 (-1.97 to -0.31)** -1.48 (-2.29 to -0.67)*** -0.34 (-1.17 to 0.49) 
RV % pred. 108.6 (36.7) a 103.5 (32.1) b 105.6 (34.2) c 5.1 (-20.3 to 30.6) 3.0 (-21.7 to 27.7) -2.1 (-26.8 to 22.5) 
TLC % pred. 104.7 (15.2) a 105.6 (10.9) b 110.9 (12.4) c -1.0 (-10.5 to 8.6) -6.3 (-15.5 to 3.0) -5.3 (-14.6 to 4.0) 
RV/TLC ratio % 106.4 (33.4) a 96.9 (26.3) b 91.5 (19.0) c 9.5 (-10.1 to 29.2) 15.0 (-4.1 to 34.0) 5.4 (-13.6 to 24.5) 
TLCO % pred. 87.4 (16.8) b 90.1 (12.6)  104.9 (11.2) -2.7 (-12.4 to 7.0) -17.6 (-27.1 to -8.1)*** -14.8 (-24.3 to -5.3)**  
KCO % pred. 86.5 (9.7) d 87.1 (10.9) c 101.5 (11.3) b -0.6 (-8.3 to 7.1) -15.0 (-22.6 to -7.4)*** -14.4 (-22.0 to -6.8)*** 
Lung clearance index 7.0 (6.7 to 7.9) e 6.1 (5.9 to 6.9) a 6.6 (5.9 to 7.0) d 0.9 (0.3 to 1.2)** 0.4 (0.1 to 1.1)* -0.5 (-0.7 to 0.3) 
FeNO ppb  19 (12 to 28) 19 (12 to 28)  27 (14 to 43) 0 (-6 to 6) -8 (-15 to 2) -8 (-16 to 2) 
Data are presented as mean (SD) or median (IQR).  
Between group comparisons made using ANOVA with Tukey-Kramer (all pairs simultaneous 95% CI) or Kruskal-Wallis ANOVA of ranks followed by Dunn’s (all pairs) test.  
*: p<0.05, **:p<0.01,***:p<0.001 
BPD: bronchopulmonary dysplasia; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; FEF25-75%: forced expiratory flow at 25-75% of FVC, % pred.: percent predicted 
measurements; ppb: parts per billion  a: n=4 missing data, b: n=2 missing data, c: n=1 missing data, d: n=3 missing data, e: n=5 missing data . 
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Table 3 Comparison of lung function variables between small for gestational age (SGA) and appropriate for gestation age (AGA) preterm 
adult survivors before and after appropriate weighting for selection probabilities of BDP and non-BPD subjects. 
 
 SGA (n=18) AGA (n=30) SGA vs. AGA (crude) SGA vs. AGA (weighted) 
Gestational age, wk 30.4 (2.4) 27.7 (2.6) 2.8 (1.3 to 4.3) *** 2.4 (1.5 to 4.1) *** 
FEV1 % pred. 88.7 (16.6) 98.5 (15.5) -9.8 (-19.3 to -0.2) * -9.1 (-19.1 to 0.8)  
FEV1 z score -1.10 (1.43) -0.32 (1.31) -0.78 (-1.60 to 0.03) -0.72 (-1.58 to 0.14) 
FVC % pred. 101.8 (15.4) 108.3 (14.4) -6.5 (-15.3 to 2.4) -5.9 (-15.1 to 3.3) 
FVC z score -0.81 (1.39) 0.37 (1.13) -0.55 (-1.29 to 0.19) -0.47 (-1.31 to 0.37) 
FEV1/FVC % pred. 75.4 (8.3) 78.8 (10.5) -3.3 (-9.2 to 2.5)  -3.1 (-9.2 to 2.9) 
FEV1/FVC z score -1.09 (0.98) -0.71 (1.16) -0.38(-1.04 to 0.28) -0.39 (-1.09 to 0.30) 
FEF 25- 75 % pred. 62.2 (24.0) 73.7 (26.4) -11.5 (-26.9 to 3.8) -10.5 (-27.0 to 6.0) 
FEF 25-75 z score -1.38 (1.28) -0.78 (1.46) -0.60 (-1.44 to  0.24) -0.56 (-1.40 to 0.28) 
RV % pred. 108.2 (31.5) a  104.9 (36.1) a 3.3 (-19.2 to 25.8) 1.2 (-21.4 to 23.7) 
TLC % pred. 103.7 (13.2) a 106.0 (13.2) a -2.3 (-10.9 to 6.3) -2.5 (-10.7 to 5.7) 
RV/TLC % pred. 108.3 (32.1) a 98.0 (28.9) a 10.3 (-9.3 to 29.8) 7.2 (-12.6 to 27.1) 
TLCO % pred. 87.3 (12.5) b 89.5 (16.0)  -2.2 (-11.4 to 7.1) -2.5 (-10.4 to 5.4) 
KCO % pred. 87.3 (11.6) a 86.6 (9.6) b 0.7 (-5.9 to 7.3)  3.1 (-4.2 to 10.5) 
lung clearance index  6.9 (6.1 to 7.0) c 6.6 (6.1 to 7.8) c 0.3 (-0.8 to 0.6) Not applicable 
FeNO, ppb 23 (12 to 28) d 19 (12 to 28) 4 (-4 to 9) Not applicable 
 Data are presented as mean (SD) or median (IQR).   
Between group comparisons made using ANOVA with Tukey-Kramer (all pairs simultaneous 95% CI) 
or Kruskal-Wallis ANOVA of ranks followed by Dunn’s (all pairs) test. 
* : p<0.05, **:p<0.01,***:p<0.001 
SGA: small for gestational age; AGA: appropriate for gestational age; FEV1: forced expiratory volume 
in 1 s; FVC: forced vital capacity; FEF25-75%: forced expiratory flow at 25-75% of FVC, % pred.: percent 
predicted measurements. an= 3 missing data, b n= 2 missing data, c n= 5 missing data, d n= 1 missing 
data.  
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Table 4: Comparison of HRCT scores and radiological findings between adult preterm BPD and non-BPD survivors 
 BPD  
(n=23) 
Non BPD  
(n=23) 
Odds Ratio (95 %CI)  
Median score (interqartile range) 6 (4 to 9) 2 (0 to 4) Not applicable 
Subpleural opacities 22 (96%) 10 (43%) 28.6 (3.3, 250) *** 
Hypoattenuation in expiration 15 (65%) 7 (30%) 4.3 (1.2, 14.7) * 
Hypoattenuation in inspiration 4 (17%) 0 (0%) - 
Subsegmental atelectasis 4 (17%) 1 (4%) 4.6 (0.5,45.1) 
Bullae 5 (22%) 0 (0%) - * 
Increased Bronchial Arterial Ratio 1 (4%) 0 (0%) - 
Bronchiectasis 1 (4%) 2 (9%) 0.5 (0.0, 5.7) 
Bronchial wall thickening 1 (4%) 2 (9%) 0.5 (0.0, 5.7) 
Emphysema 0 (0%) 1 (4%) - 
n/a: not applicable,  * : p<0.05, ***: p<0.001 
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Table 5: Exercise characteristics compared between study groups  
 BPD 
(n=22) 
Non BPD 
(n=20) 
Term 
(n=24) 
BPD vs. Non BPD BPD vs. Term Non BPD vs. Term 
       
Peak VO2, L/min  2.33 (0.56) 2.57 (0.81) 3.40 (1.03) -0.24 (-0.85 to 0.38) -1.07 (-1.66 to -0.48) *** -0.83 (-1.44 to -0.22) ** 
Peak VO2, L/min % predicted 81.2 (17.8) 87.7 (17.5) 118.3 (22.4) -6.5 (-21.0 to 8.0)  -37.1 (-50.9 to -23.3) *** -30.6 (-44.8 to -16.5) *** 
Peak VO2, ml/kg/min 35.6 (7.5) 39.3 (8.8) 45.2 (11.3) -3.7 (-10.7 to 3.3) -9.6 (-16.3 to -3.0) ** -6.0 (-12.8 to 0.9) * 
Peak VO2, ml/kg/min % predicted 81.6 (14.3) 92.0 (17.3) 107.9 (22.8) -10.5 (-24.3 to 3.39)  -26.4 (-39.6 to -13.2) ***  -15.9 (-28.5 to -2.4) * 
Distance completed on treadmill, m 966 (245)   1143 (303)  1402 (333)  -178 (-398 to 43)  -436 (-647 to -226) *** -259 (-475 to -43) * 
Cardiovascular responses 
AT as % peak VO2 50.5 (12.8) 47.6 (8.1) 63.3 (13.9) 2.9 (-6.0 to 11.8) -12.8 (-21.3 to -4.2) ** -15.7 (-24.4 to -6.9) *** 
Peak heart rate, bpm 173 (13) 180 (13) 186 (14) -7.3 (-17.3 to 2.7) -12.9 (-22.5 to -3.4) ** -5.6 (-15.5 to 4.2) 
Peak heart rate, % predicted  88.2 (7.0) 92.8 (7.2) 96.6 (7.8) -4.6 (-10.0 to 0.9) -8.4 (-13.7 to -3.2) *** -3.9 (-9.2 to 1.5) 
Ventilatory and gas exchange responses 
VE max, L/min 78.3 (22.7) 85.1 (25.7) 109.5 (36.2) -6.8 (-28.4 to 14.8)  -31.2 (-51.8 to -10.6) ** -24.4 (-45.5 to -3.2) * 
VE max, % predicted 64.0 (20.5) 54.6 (6.9) 62.9 (14.6) 9.4 (-1.9 to 20.7)  1.1 (-9.7 to 11.9) -8.3 (-19.4- to 2.7) 
Vt, L 1.75 (0.45) 2.27 (0.77) 2.75 (0.67) -0.51 (-0.99 to -0.04) * -1.00 (-1.45 to -0.55) *** -0.49 (-0.95 to -0.02) * 
Vt, %  predicted 84.6 (23.9) 88.9 (19.3) 96.2 (14.9) -4.3 (-18.8 to 10.3) -11.6 (-25.5 to 2.31)  -7.3 (-21.6 to 6.9) 
Ventilatory reserve % 36.3 (20.4) 45.4 (6.9) 37.1 (14.6) -9.1 (-20.4 to 2.2)  -0.8 (-11.5 to 10.0) 8.3 (-2.7 to 19.4) 
Peak respiratory rate 38.6 (9.1) 35.3 (6.3) 36.0 (7.2) 3.2 (-2.4 to 8.9) 2.6 (-2.8 to 8.0) -0.7 (-6.2 to 4.9) 
Respiratory exchange ratio 1.04 (0.07) 1.09 (0.09) 1.09 (0.08) -0.05 (-0.11 to 0.01) -0.06 (-0.11 to 0.00)  -0.01 (-0.07 to 0.05) 
VE/VO2 @ AT  23.9 (2.0)  22.8 (2.4)   22.2 (1.7)  1.1 (-0.4 to 2.6) 1.7 (0.2 to 3.2) * 0.6 (-0.9 to 2.1) 
VE/VCO2 @ AT  28.1 (1.9)  27.0 (2.9)  25.9 (2.3)  1.1 (-0.6 to 2.9) 2.2 (0.5 to 3.9) ** 1.1 (-0.6 to 2.8) 
SpO2 at peak  96 (95 to 98) 96 (95 to 97)   97 (96 to 98)  0 (-1 to 1)) -1 (-2 to 0)  -1 (-2 to 0) * 
Modified Borg score (0- 10)  8 (7 to 10)  9 (8 to 10)  8 (8 to 9)  -1 (-1 to 1) 0 (-1 to 1) 1 (0 to 1) 
Data are presented as mean (SD) or median (IQR). 
Between group comparisons made using ANOVA with Tukey-Kramer (all pairs simultaneous 95% CI) or Kruskal-Wallis ANOVA of ranks followed by Dunn’s (all pairs) test. 
*: p<0.05, **: p<0.01, ***:  p<0.001.   
FEV1: forced expiratory volume in 1 s , L/min: litres per minute, Vt L: tidal volume litres, Peak VO2: oxygen uptake at peak exercise, AT: anaerobic threshold, VE/VO2 @ AT: 
Ventilatory equivalent for oxygen, VE/VCO2 @ AT: Ventilatory equivalent for carbon dioxide.  
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Figure 1  
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